Drug Research

At the signing ceremony of the new research collaboration: Back row from left: Dr. Simone Gatzke, Forschungszentrum Juelich, Raphael Dumain, Dr. Isolde Häuser-Hahn and Dr. habil Guenter Welz from Bayer, Prof. Ulrich Schurr, Juelich, Dr. Samir Bennabi, Bayer. ...

GlaxoSmithKline plc and Innoviva, Inc announced the presentation of further data from the pivotal phase III FULFIL study with investigational closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg). in patients with chronic obstructive pulmonary disease...

Boehringer Ingelheim, one of the world’s 20 leading pharmaceutical companies, and Saniona, a leading biotech company in the field of ion channel drug discovery, announced that they have entered into a research collaborationwith the objective to discover and develop...

Nymox Pharmaceutical Corp is pleased to announce successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide, the Company's lead compound in late stage development for enlarged prostate for localized...

An international team of researchers - led by scientists at UC San Francisco, Stanford University, the University of North Carolina (UNC), and the Friedrich-Alexander University Erlangen-Nürnberg in Germany has developed a new opioid drug candidate that...

ViiV Healthcare announced the start of a phase III programme to support regulatory filings for a two-drug regimen of dolutegravir (Tivicay®) and lamivudine (Epivir®) as a treatment for HIV-1 infection in adults who have not received prior antiretroviral therapy....

The two most popular injectables used to transition are disappearing from shelves as one awaits re-approval by the FDA, but other factors remain murky The voice on the other the end of the phone had an...